Alphageneron Pharmaceuticals

What Alphageneron Pharmaceuticals does

Alphageneron Pharmaceuticals, Inc. is a privately-held clinical-stage biotechnology company founded in 2020 and headquartered in Boston, Massachusetts, with European research operations in Munich, Germany. The company develops targeted natural killer (NK) cell therapies supported by companion diagnostics, built around membrane Hsp70 (mHsp70), a cancer-specific biomarker that is highly expressed on aggressive and metastatic cancer cells but not on normal tissue. Alphageneron's entire NK cell platform is anchored by an exclusive worldwide license (February 2021) from Multimmune GmbH, founded by mHsp70 discoverer Gabriele Multhoff, giving the company rights to the patented TKD peptide used for ex vivo NK cell activation. The company operates with a lean team of 1-10 employees and is led by Founder/CEO Robert K. Brooks, CFO Ola Soderquist, and CSO A. Graham Pockley, with Scientific Advisor Gabriele Multhoff and a board that includes Marc Lippman (founding director of Seattle Genetics) and Robert Clarke (former CEO of Pulmatrix).

The product portfolio spans four modalities: ENKASTIM, an autologous NK cell therapy that activates a patient's own NK cells with TKD and IL-2 without genetic modification; AP-161, an allogeneic targeted NK cell therapy using cryopreserved donor NK cells similarly activated; AP-205, an off-the-shelf allogeneic CAR-engineered NK cell therapy in which gene editing is used to improve persistence and potency; and AP-401, an iPSC-derived bi-specific CAR NK cell therapy targeting CD155 and CD73. ENKASTIM has reported Phase IIa data in advanced NSCLC showing a 71% clinical benefit rate versus 28% for standard of care and a 13-month median progression-free survival versus 8 months for standard of care, and has cleared an FDA Pre-IND meeting for a proposed U.S. Phase II trial.

Commercially, Alphageneron is pre-revenue. The business model contemplates revenue from sale or licensing of NK cell therapy products upon regulatory approval, administered in outpatient settings following leukapheresis and ex vivo cell processing, and distributed via clinical trial sites in the United States and Germany today and through hospitals and specialty treatment centers post-approval. Pricing is not publicly disclosed. There are no disclosed funding rounds, institutional investors, or revenue figures; the company is reliant on founder capital, the Multimmune license, and the four-asset pipeline for future value creation, with metastatic cancers responsible for roughly 90% of cancer-related deaths representing the long-term addressable market.

Name

Alphageneron Pharmaceuticals

Legal name

Alphageneron Pharmaceuticals, Inc.

Website

https://alphageneron.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Alphageneron Pharmaceuticals is a privately-held, clinical-stage biotechnology company developing targeted natural killer (NK) cell therapies — autologous, allogeneic, CAR-engineered, and iPSC-derived — that are directed at the membrane Hsp70 (mHsp70) cancer biomarker and supported by companion diagnostics, serving patients with advanced and metastatic solid tumors.

Ownership category

akta.pro rank

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Therapeutic Product Sales: Revenue from sale of NK cell therapy products upon regulatory approval. Products include ENKASTIM™ (autologous), AP-161™ (allogeneic), AP-205™ (CAR NK), and AP-401™ (iPSC bi-specific CAR NK).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Alphageneron Pharmaceuticals is a clinical-stage biotechnology company developing allogeneic and autologous Natural Killer (NK) cell-based immunotherapies for solid tumors. Its pipeline is anchored by the ENKASTIM™ platform, which targets cancer cells expressing membrane-bound Hsp70 (mHsp70), and includes product candidates AP-161™, AP-205™, and AP-401™ across indications such as non-small cell lung cancer, head and neck cancer, and other metastatic solid tumors.

Product overview

Alphageneron Pharmaceuticals is developing a portfolio of targeted natural killer (NK) cell therapies supported by Companion Diagnostics. The company's core platform centers on membrane Hsp70 (mHsp70), a cancer-specific biomarker. The lead product ENKASTIM™ is an autologous NK cell therapy that has completed Phase IIa clinical trials. The allogeneic pipeline includes AP-161™ (non-genetically modified) and AP-205™ (CAR-engineered). AP-401™ represents an innovative iPSC-derived bi-specific CAR NK cell therapy targeting CD155 and CD73, currently in preclinical development. The platform enables both autologous (patient's own cells) and allogeneic ('off-the-shelf') approaches to treat various cancers expressing mHsp70.

Differentiator

Problem solved

Functional benefit

Brands

• ENKASTIM™: Targeted autologous NK cell therapy that activates the patient's own NK cells to target cancers expressing membrane Hsp70.
• AP-161™
• AP-205™
• AP-401™

Products and services

• ENKASTIM™ Proprietary allogeneic (off-the-shelf) Natural Killer cell immunotherapy platform engineered to selectively target cancer cells expressing the membrane-bound Hsp70 (mHsp70) biomarker. Licensed exclusively from Multimmune GmbH in February 2021.
• AP-161™ Autologous (patient-derived) NK cell therapy candidate built on the ENKASTIM platform, intended for patients with advanced and metastatic solid tumors.
• AP-205™ Allogeneic NK cell therapy candidate from the ENKASTIM platform targeting mHsp70-expressing solid tumors, including non-small cell lung cancer.
• AP-401™ Pipeline NK cell therapy candidate in Alphageneron's oncology portfolio leveraging the ENKASTIM platform.

Quantifiable outcome

• ENKASTIM™ achieved 71% clinical benefit rate (5/7 patients) vs 28% (2/7) for standard of care alone in Phase IIa NSCLC trial
• +3 more outcomes

Named customers2 records

Segments3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Multimmune GmbHcoreOEM/ Whitelabel/ Licensing Partner · 1 February 2021Exclusive license agreement signed in February 2021 for Natural Killer Cell Platform Therapy worldwide. Multimmune GmbH, founded by Dr. Gabriele Multhoff, granted Alphageneron exclusive rights to NK cell platform technology targeting membrane Hsp70. This is a foundational partnership providing core technology access for all of Alphageneron's therapeutic programs.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Nkarta Therapeutics: Nkarta is a clinical-stage biotech developing allogeneic and autologous NK cell therapies for cancer, including CAR-NK candidates. It is the most directly comparable peer to Alphageneron given overlapping modality (NK cells), cancer indications, and combination of engineered/non-engineered approaches.
• Fate Therapeutics: Fate is a clinical-stage cell therapy company developing iPSC-derived NK and T-cell therapies, including off-the-shelf NK candidates for hematologic and solid tumors. Its iPSC platform and NK cell focus directly parallel Alphageneron's AP-401 iPSC-derived bi-specific CAR NK program.
• Century Therapeutics: Century develops iPSC-derived allogeneic cell therapies including NK and T-cell candidates for cancer. Its iPSC-derived NK approach and off-the-shelf positioning make it a direct platform peer to Alphageneron's iPSC-derived AP-401 program.
• Shoreline Biosciences: Shoreline is a developer of allogeneic, off-the-shelf NK cell therapies engineered for cancer, partnering with major pharma. It is a direct peer to Alphageneron's allogeneic NK programs (AP-161, AP-205) given matching modality and cancer indications.
• Cytovia Therapeutics: Cytovia develops NK cell and NK engager therapies for cancer, including iPSC-derived NK candidates. Its NK-focused pipeline and engineered cell platform make it a direct peer to Alphageneron's NK cell therapy portfolio.
• ONK Therapeutics: ONK is a clinical-stage biotech developing off-the-shelf, gene-edited NK cell therapies for both hematologic and solid tumors. Its engineered NK cell focus parallels Alphageneron's AP-205 allogeneic CAR NK program.
• Acepodia: Acepodia develops off-the-shelf allogeneic NK cell therapies using its Antibody-Cell Conjugation (ACC) platform for cancer. Its off-the-shelf NK positioning and oncology focus make it a direct peer to Alphageneron's allogeneic NK pipeline.

Broad incumbents

• Allogene Therapeutics: Allogene is a clinical-stage leader in allogeneic CAR-T cell therapies with off-the-shelf manufacturing at scale. While focused on T-cells rather than NK cells, it is a broadly comparable cell therapy incumbent relevant to Alphageneron's off-the-shelf strategy and commercial scale ambitions.
• Iovance Biotherapeutics: Iovance is a commercial-stage cell therapy company with FDA-approved autologous tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. It is a broader cell therapy incumbent relevant to Alphageneron's autologous, solid-tumor-focused ENKASTIM program.
• Cellectis: Cellectis develops allogeneic CAR-T cell therapies using gene editing and is broadly comparable to Alphageneron's gene-edited CAR NK cell approach (AP-205). It is a platform peer in the engineered off-the-shelf cell therapy space, though focused on T-cells.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/alphageneron
• LinkedInlinkedin.com/company/alphageneron-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alphageneron Pharmaceuticals